As alluded to above, the ability of OXM to effectively activate both GCGR and GLP-1R, thereby improving blood glucose and body weight, is attractive for the development of peptide therapeutics for obesity/T2DM, provided an appropriate receptor balance is struck. Here, GLP1R is linked to type 2 diabetes mellitus.